<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Bicarbonate therapy in lactic acidosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Bicarbonate therapy in lactic acidosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Bicarbonate therapy in lactic acidosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Wiederkehr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H25392892">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lactic acidosis causes a decrease in serum bicarbonate concentration that is similar in magnitude to the increase in the lactate concentration. Lactate is a metabolizable organic anion that, when oxidized, will generate bicarbonate. Thus, if the stimulus to lactic acid production is eliminated by successful treatment of the underlying disease (eg, restoration of perfusion in a patient with shock), oxidative processes will metabolize the accumulated lactate and regenerate bicarbonate. This will correct the metabolic acidosis and reduce the anion gap.
        </p>
        <p>
         The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial [
         <a href="#rid1">
          1-5
         </a>
         ]. Most, but not all, experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis and acidemia (arterial pH less than 7.1). Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines [
         <a href="#rid1">
          1,5-10
         </a>
         ].
        </p>
        <p>
         The role of bicarbonate therapy and alternative buffering agents in patients with lactic acidosis will be discussed in this topic. The causes of lactic acidosis, the approach to the adult with metabolic acidosis, and the treatment of shock in adults are presented elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2370.html" rel="external">
          "Causes of lactic acidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2291.html" rel="external">
          "Approach to the adult with metabolic acidosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1607.html" rel="external">
          "Treatment of severe hypovolemia or hypovolemic shock in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The use of bicarbonate dialysis to correct lactic acidosis caused by
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/296.html" rel="external">
          "Metformin poisoning"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12631273">
         <span class="h1">
          OVERVIEW OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Who should be treated – In our opinion, bicarbonate therapy should be initiated when lactic acidosis has generated severe acidemia (ie, pH less than 7.1). In patients with less severe acidemia (eg, pH 7.1 to 7.2) and severe acute kidney injury (ie, a twofold or greater increase in serum creatinine or oliguria), bicarbonate therapy can potentially prevent the need for dialysis and may improve survival [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Which patients should receive bicarbonate therapy'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Goals of therapy – The primary therapy is reversal of the underlying disease (eg, shock). When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, the aim is to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed. However, if the patient has severe acute kidney injury, then the goal is to raise the pH above 7.3. (See
         <a class="local">
          'Therapeutic goal'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential harms – Rapid infusions of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         may increase the partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ), accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. There is little evidence that any alternative buffering agents are superior to sodium bicarbonate therapy. (See
         <a class="local">
          'Potential harms of bicarbonate and alternative agents'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approach – In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2 mEq/kg
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still below 7.1. (See
         <a class="local">
          'Approach'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12631281">
         <span class="h1">
          WHICH PATIENTS SHOULD RECEIVE BICARBONATE THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that patients with lactic acidosis and severe acidemia (pH less than 7.1 and serum bicarbonate level 6 mEq/L or less) receive bicarbonate therapy.
        </p>
        <p>
         In addition, we suggest bicarbonate therapy for less severe acidosis (ie, pH 7.1 to 7.2) in patients who also have severe acute kidney injury (ie, a twofold or greater increase in serum creatinine or oliguria). Bicarbonate therapy in such patients may prevent the need for dialysis and improve survival [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         If the patient's pH is 7.1 or lower and the serum bicarbonate level is greater than 6 mEq/L, then this indicates that the partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) is greater than 20 mmHg, which signifies inadequate ventilation. Such patients have mixed metabolic and respiratory acidosis, and rapid infusion of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         may worsen the respiratory acidosis. Mechanical ventilation may be necessary to achieve a lower PCO
         <sub>
          2
         </sub>
         level and raise the pH in these patients with severe acidemia due to mixed acidosis.
        </p>
        <p>
         Data supporting the use of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         therapy when the pH is below 7.1 are lacking. However, we suggest its use in such patients because it may treat or prevent the following adverse clinical effects of acidemia, each of which can produce hemodynamic instability [
         <a href="#rid1">
          1,5-10,12
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced left ventricular contractility
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arrhythmias
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arterial vasodilation and venoconstriction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired responsiveness to catecholamine vasopressors
        </p>
        <p>
        </p>
        <p>
         In addition, relatively small bicarbonate concentration changes will have a large pH impact when the serum bicarbonate concentration is markedly reduced (doubling the bicarbonate concentration, for example from 2 to 4 mEq/L, without a change in PCO
         <sub>
          2
         </sub>
         will raise the pH by 0.3 units).
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          Sodium bicarbonate
         </a>
         infusion will also expand the extracellular fluid (ECF) volume, an effect that can be beneficial or deleterious, depending upon the patient's preinfusion volume status.
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         generally use bicarbonate therapy in patients with less severe acidosis (pH 7.1 or greater), unless the patient also has severe acute kidney injury. The best data come from a randomized trial of 389 critically ill patients with metabolic acidosis (mean serum bicarbonate, 13 mmol/L), elevated lactate (mean lactate, 5.8 mmol/L, and more than 80 percent of patients had levels greater than or equal to 2 mmol/L), and less severe acidemia (mean arterial pH, 7.15) who were assigned to either intravenous infusions of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         (to maintain a pH greater than 7.3) or to no sodium bicarbonate [
         <a href="#rid11">
          11
         </a>
         ]. Bicarbonate therapy had no statistically significant effect on mortality at 28 days (45 versus 54 percent) or organ failure at 7 days (62 versus 69 percent). However, among the subgroup of patients with severe acute kidney injury (defined as a twofold or greater increase in serum creatinine or oliguria), bicarbonate therapy reduced 28-day mortality (46 versus 63 percent) and the need for dialysis (51 versus 73 percent).
        </p>
        <p>
         However, as discussed below, patients should generally be adequately ventilated before bicarbonate therapy is given. (See
         <a class="local">
          'Potential harms of bicarbonate and alternative agents'
         </a>
         below.)
        </p>
        <p>
         The use of bicarbonate therapy in patients with cardiac arrest is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/278.html" rel="external">
          "Advanced cardiac life support (ACLS) in adults", section on 'Medications used during CPR'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12631289">
         <span class="h1">
          THERAPEUTIC GOAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary aim of therapy is
         <strong>
          reversal of the underlying disease
         </strong>
         (eg, shock, sepsis). Tissue hypoxia may dramatically increase lactic acid production, often coupled with reduced metabolic clearance of lactate by the liver, heart, and kidneys. This combination of overproduction and underutilization can easily overwhelm any attempt to increase the serum bicarbonate with exogenously administered alkali. In fact, as discussed below, alkali therapy may accelerate lactic acid production. Thus, unless the pathologic process causing the excessive production of lactic acid can be reversed, any beneficial effect of exogenous bicarbonate will be transient. (See
         <a class="local">
          'Potential harms of bicarbonate and alternative agents'
         </a>
         below.)
        </p>
        <p>
         When using bicarbonate therapy in patients with lactic acidosis and severe acidemia, we aim to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed. For the group of patients with severe acute kidney injury, the pH goal is 7.3 or higher.
        </p>
        <p class="headingAnchor" id="H12631806">
         <span class="h1">
          POTENTIAL HARMS OF BICARBONATE AND ALTERNATIVE AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H12632674">
         <span class="h2">
          Potential harms of bicarbonate therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid infusions of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         have a number of potentially adverse effects:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increased arterial and tissue capillary partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acceleration of lactate generation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced ionized calcium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypernatremia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extracellular fluid (ECF) volume expansion
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12632681">
         <span class="h3">
          Increased PCO2
         </span>
         <span class="headingEndMark">
          —
         </span>
         The infused bicarbonate must undergo several metabolic steps to effectively raise the pH. First, it combines with a hydrogen ion to form carbonic acid (H
         <sub>
          2
         </sub>
         CO
         <sub>
          3
         </sub>
         ). Second, H
         <sub>
          2
         </sub>
         CO
         <sub>
          3
         </sub>
         dehydrates to carbon dioxide (CO
         <sub>
          2
         </sub>
         ), and water (H
         <sub>
          2
         </sub>
         O). Then the CO
         <sub>
          2
         </sub>
         must be removed from the tissue bed and from the body by circulation and respiration. If the CO
         <sub>
          2
         </sub>
         generated by infused bicarbonate is not efficiently removed, then the resulting increase in PCO
         <sub>
          2
         </sub>
         will prevent carbonic acid dehydration and the pH will not increase. Consequently, adequate perfusion and ventilation is a prerequisite to the effective use of exogenous bicarbonate.
        </p>
        <p>
         Even with adequate ventilation, the PCO
         <sub>
          2
         </sub>
         is likely to transiently rise at the local tissue level when bicarbonate is infused rapidly. Because CO
         <sub>
          2
         </sub>
         readily penetrates cell membranes, this increase in tissue PCO
         <sub>
          2
         </sub>
         may worsen intracellular acidosis even as arterial blood pH increases. This dissociation between tissue and systemic arterial acid-base parameters is magnified in patients with circulatory failure [
         <a href="#rid13">
          13,14
         </a>
         ].
        </p>
        <p>
         The cerebrospinal fluid (CSF) pH may also fall when bicarbonate is infused for two reasons: first, the mechanism described above increases the PCO
         <sub>
          2
         </sub>
         locally in the brain and CSF; second, amelioration of systemic acidemia (ie, the rise in arterial blood pH) diminishes the drive for hyperventilation, causing the systemic PCO
         <sub>
          2
         </sub>
         to increase. Any systemic and/or local increase in PCO
         <sub>
          2
         </sub>
         will be quickly reflected within the CSF. By contrast, an increased blood bicarbonate concentration is only slowly transmitted to the CSF. Because CSF bicarbonate concentration does not rise as rapidly as the CSF PCO
         <sub>
          2
         </sub>
         , a "paradoxical" reduction in CSF pH may occur and this phenomenon has been associated with neurologic deterioration [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12632935">
         <span class="h3">
          Acceleration of lactate generation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acidemia will act as a "brake" on lactic acid generation by inhibiting glycolysis, largely mediated by a reduction in the activity of the enzyme, phosphofructokinase [
         <a href="#rid17">
          17
         </a>
         ]. Thus, increasing pH with exogenous bicarbonate may accelerate the production of lactate.
        </p>
        <p class="headingAnchor" id="H12632964">
         <span class="h3">
          Effects on calcium, sodium, and extracellular fluid volume
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increase in pH can decrease the ionized calcium concentration, which may adversely affect cardiac function [
         <a href="#rid9">
          9,18
         </a>
         ]. Because
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         is usually infused as a hypertonic solution (8.4 percent), a 50 mL ampule containing 50 mEq of sodium bicarbonate (1000 mmol/L) will raise the serum sodium concentration of a 70 kg person by approximately 1 mEq/L and expand the ECF volume by approximately 250 mL.
        </p>
        <p class="headingAnchor" id="H12631930">
         <span class="h2">
          Alternatives to bicarbonate therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The limitations and potential deleterious effects of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         therapy in patients with lactic acidosis have prompted investigation of alternative buffering agents:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10027" href="/z/d/drug information/10027.html" rel="external">
          Tromethamine
         </a>
         or tris-hydroxymethyl aminomethane (THAM) is an amino alcohol that buffers protons by virtue of its amine (NH
         <sub>
          2
         </sub>
         ) moiety (pKa = 7.7). The potential advantage of THAM is that, unlike bicarbonate (HCO
         <sub>
          3
         </sub>
         ), which generates CO
         <sub>
          2
         </sub>
         , this chemical reduces CO
         <sub>
          2
         </sub>
         [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carbicarb is an equimolar mixture of sodium carbonate (Na
         <sub>
          2
         </sub>
         CO
         <sub>
          3
         </sub>
         ) and
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         (NaHCO
         <sub>
          3
         </sub>
         ) that generates less CO
         <sub>
          2
         </sub>
         than HCO
         <sub>
          3
         </sub>
         [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dichloroacetate (DCA) is an investigational drug that increases the activity of the enzyme pyruvate dehydrogenase and therefore accelerates mitochondrial oxidation of pyruvate and lactate metabolism [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Each of these alternatives to NaHCO
         <sub>
          3
         </sub>
         has been studied and, despite certain theoretical advantages,
         <strong>
          none
         </strong>
         have been proven to be more effective or safer [
         <a href="#rid20">
          20,22-28
         </a>
         ]. In addition, none of these agents are available for use in the United States.
        </p>
        <p class="headingAnchor" id="H12631304">
         <span class="h1">
          APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         In critically ill patients with severe lactic acidosis, which has resulted in severe acidemia (pH less than 7.1 and serum bicarbonate concentration 6 mEq/L or less), we suggest the following approach in regard to bicarbonate therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assure that the patient is adequately ventilated; this is a prerequisite to the effective use of exogenous bicarbonate in patients with lactic acidosis. In nonintubated patients with severe acidemia, an appropriate ventilatory response to the metabolic acidosis should reduce the partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ) to at least 15 mmHg and often to 10 to 12 mmHg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If bicarbonate administration raises the pH, this can reduce the ionized calcium concentration and have adverse hemodynamic consequences. Ideally, the ionized calcium should be measured and treated if it falls. However, in many facilities, this measurement may not be readily available within the required time frame. Under such circumstances, if the blood pressure falls or does not improve, and if the ionized calcium could be low, then empiric calcium infusion should be considered [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If ventilation is adequate, the patient with severe lactic acidosis (pH less than 7.1) should be given an intravenous
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         bolus of 1 to 2 mEq/kg body weight. The serum electrolytes and blood pH should be measured 30 to 60 minutes later, and the dose of sodium bicarbonate can be repeated if severe lactic acidosis (pH less than 7.1) persists.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We prefer this empiric approach to the dosing of bicarbonate, rather than calculating the dose based upon the "bicarbonate distribution space." The bicarbonate distribution space is a virtual concept and not a true anatomic space. Its size varies markedly with the severity of the metabolic acidosis. In addition, since bicarbonate can be rapidly generated or decomposed, its apparent distribution space can change dramatically.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If several doses of NaHCO
         <sub>
          3
         </sub>
         do not increase the pH above 7.1 and all other appropriate therapeutic interventions have been undertaken, then further NaHCO
         <sub>
          3
         </sub>
         therapy should continue in the form of a near-isotonic solution of NaHCO
         <sub>
          3
         </sub>
         . This can be prepared by adding 3 ampules of NaHCO
         <sub>
          3
         </sub>
         (8.4 percent) to a liter of 5% dextrose in water (D5W), which results in a solution of 150 mEq/L NaHCO
         <sub>
          3
         </sub>
         in D5W. This has the advantage of being relatively isotonic but does increase the volume given to the patient. If volume overload is an issue and kidney function is compromised, then dialytic therapy can be instituted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dialytic therapy may be particularly effective in the treatment of otherwise refractory lactic acidosis [
         <a href="#rid29">
          29
         </a>
         ]. Usually, a continuous form of dialytic therapy is used to minimize hemodynamic problems. Several advantages of such intervention include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The administration of bicarbonate while maintaining or improving the patient's volume status
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Avoidance of hypertonicity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maintenance of a normal ionized calcium
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Removal of toxins associated with lactic acidosis (eg,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , alcohols) (see
         <a class="medical medical_review" href="/z/d/html/296.html" rel="external">
          "Metformin poisoning"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H709696017">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12631328">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The role of exogenous bicarbonate therapy in patients with lactic acidosis is controversial. Most experts believe that it is appropriate to use bicarbonate in acutely ill patients with profound lactic acidosis that has generated an arterial pH less than 7.1 and a serum bicarbonate of 6 mEq/L or less. Such severe acidemia may produce hemodynamic instability as a result of reduced left ventricular contractility, arterial vasodilation, and impaired responsiveness to catecholamines. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The following general approach applies to the use of bicarbonate therapy in patients with lactic acidosis (see
         <a class="local">
          'Overview of therapy'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The primary therapy for lactic acidosis is reversal of the underlying disease
         <strong>
         </strong>
         (eg, shock). (See
         <a class="local">
          'Therapeutic goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with lactic acidosis that has generated severe acidemia (arterial pH less than 7.1 [usually accompanied by a serum bicarbonate of 6 mEq/L or less]), we suggest
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         therapy rather than no alkali therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Which patients should receive bicarbonate therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The goal of bicarbonate therapy in patients with lactic acidosis and severe acidemia is to maintain the arterial pH above 7.1 until the primary process causing the metabolic acidosis can be reversed. (See
         <a class="local">
          'Therapeutic goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In adequately ventilated patients with lactic acidosis and severe acidemia, we give 1 to 2 mEq/kg
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         as an intravenous bolus. We repeat this dose after 30 to 60 minutes if the pH is still less than 7.1. (See
         <a class="local">
          'Approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with lactic acidosis that has generated less severe acidemia (ie, arterial pH 7.1 to 7.2), we suggest
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         therapy, rather than no alkali therapy, if severe acute kidney injury is also present (defined as a twofold or greater increase in serum creatinine or oliguria) (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We generally target a pH of 7.3 or higher in such patients. We do
         <strong>
          not
         </strong>
         typically give sodium bicarbonate to patients with arterial pH 7.1 or higher if they do not have severe acute kidney injury. (See
         <a class="local">
          'Which patients should receive bicarbonate therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid infusions of
         <a class="drug drug_general" data-topicid="9928" href="/z/d/drug information/9928.html" rel="external">
          sodium bicarbonate
         </a>
         may increase the partial pressure of carbon dioxide (PCO
         <sub>
          2
         </sub>
         ), accelerate the production of lactate, lower the ionized calcium, expand the extracellular space, and raise the serum sodium concentration. (See
         <a class="local">
          'Potential harms of bicarbonate and alternative agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is little evidence that any alternative buffering agents are superior to bicarbonate therapy. (See
         <a class="local">
          'Potential harms of bicarbonate and alternative agents'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kraut JA, Kurtz I. Use of base in the treatment of severe acidemic states. Am J Kidney Dis 2001; 38:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest 2000; 117:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacpoole PW. Lactic acidosis: the case against bicarbonate therapy. Ann Intern Med 1986; 105:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraut JA, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach. Nat Rev Nephrol 2012; 8:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh JD, Margolis TI, Kim D. Mechanism of diminished contractile response to catecholamines during acidosis. Am J Physiol 1988; 254:H20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JH, Wildenthal K, Johnson RL Jr. The effects of acid-base disturbances on cardiovascular and pulmonary function. Kidney Int 1972; 1:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teplinsky K, O'Toole M, Olman M, et al. Effect of lactic acidosis on canine hemodynamics and left ventricular function. Am J Physiol 1990; 258:H1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orchard CH, Kentish JC. Effects of changes of pH on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathieu D, Neviere R, Billard V, et al. Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study. Crit Care Med 1991; 19:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet 2018; 392:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orchard CH, Cingolani HE. Acidosis and arrhythmias in cardiac muscle. Cardiovasc Res 1994; 28:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weil MH, Rackow EC, Trevino R, et al. Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation. N Engl J Med 1986; 315:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adrogué HJ, Rashad MN, Gorin AB, et al. Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood. N Engl J Med 1989; 320:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Posner JB, Plum F. Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med 1967; 277:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris LR, Murphy MB, Kitabchi AE. Bicarbonate therapy in severe diabetic ketoacidosis. Ann Intern Med 1986; 105:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hood VL, Tannen RL. Protection of acid-base balance by pH regulation of acid production. N Engl J Med 1998; 339:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lang RM, Fellner SK, Neumann A, et al. Left ventricular contractility varies directly with blood ionized calcium. Ann Intern Med 1988; 108:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nahas GG, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs 1998; 55:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bersin RM, Arieff AI. Improved hemodynamic function during hypoxia with Carbicarb, a new agent for the management of acidosis. Circulation 1988; 77:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacpoole PW, Nagaraja NV, Hutson AD. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003; 43:683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gazmuri RJ, von Planta M, Weil MH, Rackow EC. Cardiac effects of carbon dioxide-consuming and carbon dioxide-generating buffers during cardiopulmonary resuscitation. J Am Coll Cardiol 1990; 15:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blecic S, De Backer D, Deleuze M, et al. Correction of metabolic acidosis in experimental CPR: a comparative study of sodium bicarbonate, carbicarb, and dextrose. Ann Emerg Med 1991; 20:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kette F, Weil MH, von Planta M, et al. Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation. Circulation 1990; 81:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung JM, Landow L, Franks M, et al. Safety and efficacy of intravenous Carbicarb in patients undergoing surgery: comparison with sodium bicarbonate in the treatment of mild metabolic acidosis. SPI Research Group. Study of Perioperative Ischemia. Crit Care Med 1994; 22:1540.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 1992; 327:1564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori M, Yamagata T, Goto T, et al. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 2004; 26:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraut JA, Madias NE. Lactic Acidosis: Current Treatments and Future Directions. Am J Kidney Dis 2016; 68:473.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2294 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11576874" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Use of base in the treatment of severe acidemic states.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10631227" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sodium bicarbonate for the treatment of lactic acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3014943" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lactic acidosis: the case against bicarbonate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20069275" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22945490" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Treatment of acute metabolic acidosis: a pathophysiologic approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2827525" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Mechanism of diminished contractile response to catecholamines during acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4599247" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effects of acid-base disturbances on cardiovascular and pulmonary function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2331007" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effect of lactic acidosis on canine hemodynamics and left ventricular function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2193525" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of changes of pH on the contractile function of cardiac muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1935152" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of bicarbonate therapy on hemodynamics and tissue oxygenation in patients with lactic acidosis: a prospective, controlled clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29910040" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7954638" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Acidosis and arrhythmias in cardiac muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3088448" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Difference in acid-base state between venous and arterial blood during cardiopulmonary resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2535633" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Assessing acid-base status in circulatory failure. Differences between arterial and central venous blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4378309" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Spinal-fluid pH and neurologic symptoms in systemic acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3096181" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Bicarbonate therapy in severe diabetic ketoacidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738091" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Protection of acid-base balance by pH regulation of acid production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3248127" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Left ventricular contractility varies directly with blood ionized calcium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9506241" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Guidelines for the treatment of acidaemia with THAM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2826046" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Improved hemodynamic function during hypoxia with Carbicarb, a new agent for the management of acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12856382" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Efficacy of dichloroacetate as a lactate-lowering drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2105347" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cardiac effects of carbon dioxide-consuming and carbon dioxide-generating buffers during cardiopulmonary resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1847612" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Correction of metabolic acidosis in experimental CPR: a comparative study of sodium bicarbonate, carbicarb, and dextrose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2158865" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Buffer agents do not reverse intramyocardial acidosis during cardiac resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7924363" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Safety and efficacy of intravenous Carbicarb in patients undergoing surgery: comparison with sodium bicarbonate in the treatment of mild metabolic acidosis. SPI Research Group. Study of Perioperative Ischemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1435883" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15351081" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18766181" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27291485" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lactic Acidosis: Current Treatments and Future Directions.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
